Does tumor mutational status correlate with clinical response to imatinib?

Article metrics

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1

    Corless CL et al. (2004) Biology of gastrointestinal stromal tumors. J Clin Oncol 22: 3813–3825

  2. 2

    Debiec-Rychter M et al. (2004) Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 40: 689–695

  3. 3

    Heinrich MC et al. (2003) Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 21: 4342–4349

  4. 4

    Verweij J et al. (2004) Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 364: 1127–1134

  5. 5

    Heinrich M et al. (2006) Sunitinib (SU) response in imatinib-resistant (IM-R) GIST correlates with KIT and PDGFRA mutation status [abstract]. ASCO Annual Meeting Proceedings. 24: 520S–520S

Download references

Acknowledgements

The synopsis was written by Petra Roberts, Associate Editor, Nature Clinical Practice.

Author information

Correspondence to Michael C Heinrich.

Ethics declarations

Competing interests

Christopher Corless and Michael Heinrich have received research support from and are consultants for Novartis and Pfizer, and are also members of the Speaker's Bureau for Novartis.

Rights and permissions

Reprints and Permissions

About this article

Further reading